Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II
Public ClinicalTrials.gov record NCT05047185. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Double-blind, Placebo-controlled, Randomized, Dose-ranging, Parallel Group Study to Evaluate the Safety and Efficacy of PHA-022121 Administered Orally for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Due to C1-Inhibitor Deficiency (Type I or Type II)
Study identification
- NCT ID
- NCT05047185
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Pharvaris Netherlands B.V.
- Industry
- Enrollment
- 34 participants
Conditions and interventions
Conditions
- Hereditary Angioedema
- Hereditary Angioedema Type I
- Hereditary Angioedema Type II
- Hereditary Angioedema Types I and II
- Hereditary Angioedema Attack
- Hereditary Angioedema With C1 Esterase Inhibitor Deficiency
- Hereditary Angioedema - Type 1
- Hereditary Angioedema - Type 2
- C1 Esterase Inhibitor Deficiency
- C1 Inhibitor Deficiency
Interventions
- Deucrictibant low dose Drug
- Deucrictibant high dose Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 18, 2022
- Primary completion
- Jun 29, 2025
- Completion
- Jun 29, 2025
- Last update posted
- Jul 29, 2025
2022 – 2025
United States locations
- U.S. sites
- 3
- U.S. states
- 3
- U.S. cities
- 3
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Study site | Birmingham | Alabama | 35209 | — |
| Study site | Paradise Valley | Arizona | 85253 | — |
| Study site | St Louis | Missouri | 63141 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05047185, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 29, 2025 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05047185 live on ClinicalTrials.gov.